Dynavax Technologies Corporation (DVAX) was Downgraded by RBC Capital Mkts to ” Sector Perform” while Lowering the Price Target of the company shares to $ 17 from a previous price target of $48 . Earlier the firm had a rating of “Outperform ” on the company shares. RBC Capital Mkts advised their investors in a research report released on Apr 28, 2016.
Many Wall Street Analysts have commented on Dynavax Technologies Corporation. Dynavax Technologies Corporation was Downgraded by JP Morgan to ” Neutral” on Apr 27, 2016.
On the company’s financial health, Dynavax Technologies Corporation reported $-0.70 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Mar 8, 2016. Analyst had a consensus of $-0.73. The company had revenue of $.69 million for the quarter, compared to analysts expectations of $1.53 million. The company’s revenue was down -70.2 % compared to the same quarter last year.
Dynavax Technologies Corporation closed down -2.45 points or -11.68% at $18.53 with 35,80,803 shares getting traded on Wednesday. Post opening the session at $18.31, the shares hit an intraday low of $17.75 and an intraday high of $18.96 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Oct 9, 2015, Robert Janssen (Vice President) purchased 100 shares at $23.34 per share price.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants cancer immunotherapy and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B an investigational adult hepatitis B vaccine is in Phase III clinical trials; SD-101 a cancer immunotherapy candidate is in Phase I/II clinical trials; AZD1419 a candidate drug for asthma is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.